ASCO 2020

Area: Oncology

Location: Online, Virtual

Date: May 29 to May 31


Search in Scientific Content:
Date
Filters:
KEYNOTE-20
7:11

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab versus brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma

Presenter: John Kuruvilla
Oncology
Update on
14:57

Update on state-of-the-art therapy in lung cancer

Presenter: Solange Peters
Oncology
GU cancer
12:02

GU cancer highlights of ASCO 2020

Presenter: Ignacio Duran
Oncology
Melanoma h
19:40

Melanoma highlights of ASCO 2020

Presenter: Michael A. Postow
Oncology
Osimertini...
8:15

Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA

Presenter: David R. Spigel
Oncology
Trifluridi...
9:28

Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective “real life” study

Presenter: Clélia Coutzac
Oncology
Highlights
20:32

Highlights of ASCO

Presenter: Jeffrey Weber
Oncology
First safe
8:49

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in resectable stage III melanoma

Presenter: Irene Reijers
Oncology
Maintenanc
10:18

Maintenance avelumab + best supportive care versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma: JAVELIN Bladder 100 phase III interim analysis

Presenter: Elizabeth R. Plimack
Oncology
Carfilzomi
4:22

Carfilzomib, lenalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: Results of ENDURANCE phase III trial

Presenter: Shaji Kumar
Oncology
Updated re
3:13

Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Presenter: Shaji Kumar
Oncology
Pembrolizu
3:56

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study

Presenter: Thierry Andre
Oncology
Immune che
7:58

Immune checkpoint inhibitor therapy in colorectal cancer

Presenter: Thierry Andre
Oncology

ELCC 2022

2022-03-30 - 2022-04-02
Online, Virtual

SABCS 2021

2021-12-07 - 2021-12-10
Online, Virtual

ESMO 2021

2021-09-17 - 2021-09-21
Online, Virtual

ASCO 2021

2021-06-04 - 2021-06-08
Online, Virtual

St. Gallen BCC 2021

2021-03-17 - 2021-03-21
Online, Virtual

SABCS 2020

2020-12-08 - 2020-12-11
Online, Virtual

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States